Payment overview · 2025
General Payments
$566.40
27 reported records · 10 companies
Healthcare provider profile · identity verified
Mallory Shillinger, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · ATHENS, GA · NPI 1023466570
Verified facts
What the public records show
CMS Open Payments records show Mallory Shillinger, D.O. received $566.40 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $263.66 | 46.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $106.09 | 18.7% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.75 | 7.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.51 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.75 | 5.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.00 | 3.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.60 | 3.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $19.13 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.96 | 2.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.95 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.40 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $193.92 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.93 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.78 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.46 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.75 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 459 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 103 |
| Losartan Potassium | Losartan Potassium | 387 | 113 |
| Omeprazole | Omeprazole | 212 | 74 |
| Famotidine | Famotidine | 206 | 66 |
| Metformin Hcl Er | Metformin Hcl | 188 | 60 |
| Sertraline Hcl | Sertraline Hcl | 186 | 61 |
| Lisinopril | Lisinopril | 171 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 59 |
| Gabapentin | Gabapentin | 167 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 40 |
| Mounjaro | Tirzepatide | 140 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 36 |
| Simvastatin | Simvastatin | 124 | 37 |
| Trazodone Hcl | Trazodone Hcl | 124 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 34 |
| Azelastine Hcl | Azelastine Hcl | 104 | 45 |
| Eliquis | Apixaban | 104 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 25 |
| Metformin Hcl | Metformin Hcl | 97 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 31 |
| Tramadol Hcl | Tramadol Hcl | 83 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 27 |
| Bupropion Xl | Bupropion Hcl | 73 | 23 |
| Alprazolam | Alprazolam | 72 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 18 |
| Ozempic | Semaglutide | 64 | 14 |
| Montelukast Sodium | Montelukast Sodium | 62 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 17 |
| Meloxicam | Meloxicam | 57 | 30 |
| Furosemide | Furosemide | 55 | 18 |
| Nifedipine Er | Nifedipine | 52 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 17 |
| Farxiga | Dapagliflozin Propanediol | 49 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 14 |
| Potassium Chloride | Potassium Chloride | 48 | 21 |
| Spironolactone | Spironolactone | 48 | 18 |
| Allopurinol | Allopurinol | 47 | 12 |
| Lorazepam | Lorazepam | 43 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 14 |
| Estradiol | Estradiol | 42 | 22 |
| Januvia | Sitagliptin Phosphate | 40 | 11 |
| Clonazepam | Clonazepam | 39 | 14 |
| Valsartan | Valsartan | 39 | 13 |
| Carvedilol | Carvedilol | 38 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 16 |
| Glimepiride | Glimepiride | 37 | 13 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Chlorthalidone | Chlorthalidone | 33 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 12 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 19 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 11 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 16 |
| Methylprednisolone | Methylprednisolone | 27 | 25 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Atenolol | Atenolol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | 12 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Fluconazole | Fluconazole | 15 | 12 |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.40 · 27 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Heplisav-B, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, Rybelsus, TZIELD, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error